Efficacy and safety of add-on sotatercept therapy for pulmonary arterial hypertension. A systematic review and meta-analysis.
文献摘要
Introduction Sotatercept is an FDA first-in-class activin signaling inhibitor for the treatment of pulmonary arterial hypertension (PAH). Objectives This systematic review and meta-analysis evaluate the clinical efficacy and safety of add-on sotatercept in PAH. Methods Public databases were searched from inception to May 15, 2026 for RCTs and cohort studies of adult PAH patients receiving add-on sotatercept. Primary outcomes included 6-minute walking distance (6MWD), all-cause mortality, hospitalization, NT-proBNP, pulmonary vascular resistance (PVR), and WHO-Functional Class. Secondary outcomes comprised adverse events, bleeding events, cardiometabolic outcomes, and other tolerability outcomes. Results Six studies comprising 2769 patients were included. Sotatercept significantly improved 6MWD (MD: 25.15 m; 95% CI: 7.86 to 42.44) and WHO-FC (OR: 2.34; 95% CI: 1.78 to 3.18) and reduced PVR (MD: -254.23 dyn·sec·cm⁻⁵; 95% CI: -334.46 to -174.00), NT-proBNP (-540.21 pg/mL; 95% CI; -871.47 to -208.96), right ventricular failure (OR: 0.22; 95% CI: 0.09 to 0.51), peripheral edema (OR: 0.47; 95% CI: 0.28 to 0.78) The pooled analyses also suggested reductions in hospitalization (OR: 0.41; 95% CI: 0.20 to 0.84; P = 0.01) and all-cause mortality (OR:0.50; 95% CI: 0.36 to 0.70), although the certainty was limited by the available evidence. Most safety outcomes were comparable to placebo; however, bleeding events were more frequent with sotatercept. Conclusion Add-on sotatercept significantly improved exercise capacity, functional status, biomarker profiles, hemodynamic parameters and clinical profiles, with side effects being generally comparable with control. These findings support the use of sotatercept as an effective targeted add-on therapy to background treatment. (PROSPERO; CRD420261415041).